

chain nodes :

11 12 14 16

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

1-11 5-12 12-14 14-16

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10

exact/norm bonds :

1-2 1-6 1-11 2-3 2-7 3-4 3-10 4-5 5-6 5-12 7-8 8-9 9-10 12-14 14-16

isolated ring systems :

containing 1 :

G1:O,N

G2:C,S

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
12:CLASS 14:CLASS 16:CLASS

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L1 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\08812508.str

L2 STRUCTURE UPLOADED

=> que L2 NOT L1


L3 QUE L2 NOT L1

=> d 13

L3 HAS NO ANSWERS

L1 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L2 STR



G1 O,N

G2 C,S

Structure attributes must be viewed using STN Express query preparation.

L3 QUE L2 NOT L1

=> s 13 sss sam

SAMPLE SEARCH INITIATED 19:51:11 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 189 TO ITERATE

100.0% PROCESSED 189 ITERATIONS

14 ANSWERS

SEARCH TIME: 00.00.02

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 2956 TO 4604

PROJECTED ANSWERS: 56 TO 504

L4 14 SEA SSS SAM L2 NOT L1

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L5 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\08812508.str

L6 STRUCTURE UPLOADED

=> que L6 NOT L5


L7 QUE L6 NOT L5

=> d 17

L7 HAS NO ANSWERS

L5 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L6 STR



G1 O,N

G2 C,S

Structure attributes must be viewed using STN Express query preparation.

L7 QUE L6 NOT L5

=> s 17 sss sam

SAMPLE SEARCH INITIATED 19:52:58 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 189 TO ITERATE

100.0% PROCESSED 189 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 2956 TO 4604

PROJECTED ANSWERS: 0 TO 0

L8 0 SEA SSS SAM L6 NOT L5

08/812,508

=> s 17 sss ful
FULL SEARCH INITIATED 19:53:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3985 TO ITERATE

100.0% PROCESSED 3985 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS

L9 0 SEA SSS FUL L6 NOT L5

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L10 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\08812508.str

L11 STRUCTURE UPLOADED

=> que L11 NOT L10


L12 QUE L11 NOT L10

=> d 112

L12 HAS NO ANSWERS

L10 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L11 STR



G1 O,N

G2 C,S

Structure attributes must be viewed using STN Express query preparation.

L12 QUE L11 NOT L10

=> s 112 sss sam

SAMPLE SEARCH INITIATED 19:54:21 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 189 TO ITERATE

08/812,508

100.0% PROCESSED 189 ITERATIONS
SEARCH TIME: 00.00.01

14 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2956 TO 4604
PROJECTED ANSWERS: 56 TO 504

L13 14 SEA SSS SAM L11 NOT L10

=> s l12 sss ful
FULL SEARCH INITIATED 19:54:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3985 TO ITERATE

100.0% PROCESSED 3985 ITERATIONS
SEARCH TIME: 00.00.01

198 ANSWERS

L14 198 SEA SSS FUL L11 NOT L10

=> s l14
L15 27 L14

=> d l15 1-27 bib,ab,hitstr

L15 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2003:150617 CAPLUS

DN 138:187785

TI Preparation of 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors

IN Lavalette, Remi; Gaudilliere, Bernard

PA Warner-Lambert Company, USA

SO Eur. Pat. Appl., 29 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1285922	A1	20030226	EP 2001-402166	20010813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2003016314	A1	20030227	WO 2002-EP7061	20020626
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003069260	A1	20030410	US 2002-211134	20020802
PRAI EP 2001-402166	A	20010813		

OS MARPAT 138:187785

AB The title compds. [I; R1 = OH, halo, NO₂, etc.; R2 = (un)substituted alkyl, X2(cycloalkyl) (wherein X2 = a bond, alkylene); R3 = II, III (n = 1-4; Ar = 5-6 membered arom. ring contg. 0-3 heteroatoms chosen from O, S and N; Y1-Y3 = H, OH, SH, etc.)], useful for the treatment of pathologies in which therapy by a PDE4 inhibitor is relevant, were prepd. Thus, hydrogenation of 4-benzyl-1-cyclopentyl-7-(N-methylacetamido)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one (prepn. given) over Pd/C followed by alkylation of the intermediate with 4-NCC6H4CH₂Br afforded I [R1 = 7-(N-methylacetamido); R2 = cyclopentyl; R3 = 4-NCC6H4CH₂] which showed IC₅₀ of 1.3 .mu.M against PDE4.

IT 499783-85-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors)

RN 499783-85-6 CAPLUS

CN Cyclopentanecarboxylic acid, 2-[6-bromo-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]hydrazide (9CI) (CA INDEX NAME)

08/812,508



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:157743 CAPLUS

DN 136:217047

TI Preparation of novel phenylalanine derivatives having .alpha.4 integrin-inhibitory activity

IN Makino, Shingo; Okuzumi, Tatsuya; Yoshimura, Toshihiko; Satake, Yuko; Suzuki, Nobuyasu; Izawa, Hiroyuki; Sagi, Kazuyuki; Chiba, Akira; Nakanishi, Eiji; Murata, Masahiro; Tsuji, Takashi

PA Ajinomoto Co., Inc., Japan

SO PCT Int. Appl., 137 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

not prior

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002016329	A1	20020228	WO 2001-JP7039	20010815
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2001078740	A5	20020304	AU 2001-78740	20010815
	EP 1288205	A1	20020305	EP 2001-956901	20010815
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 3440469	B2	20030825	JP 2002-521430	20010815
	NO 2003000744	A	20030407	NO 2003-744	20030217
PRAI	JP 2000-248728	A	20000818		
	JP 2001-147451	A	20010517		
	WO 2001-JP7039	W	20010815		
OS	MARPAT 136:217047				
AB	Phenylalanine derivs. [I; A = Q, Q1, Q2, Q3; wherein Arm = cyclic alkyl or arom. ring contg. 1-4 heteroatom(s) selected from O, S, and N; U, V, X = CO, SO2, CR5R6, C(:CR5R6), C:S, S:O, P(O)OH, P(O)H; W = CR7, N; wherein R1 - R7 = H, H, halo, OH, (un)substituted lower alkyl, alkenyl, or alkynyl, cycloalkyl optionally contg. a heteroatom in the ring, aryl, heteroaryl, etc.; B = HO, lower alkoxy, hydroxyamino; C = H, lower alkyl, alkenyl, alkynyl, cycloalkyl-lower alkyl (optionally contg. an heteroatom in the ring), aryl-lower alkyl, heteroaryl-lower alkyl; D = lower alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkyl-lower alkyl (optionally contg. an heteroatom in the ring), aryl, aryl-lower alkyl, heteroaryl-lower alkyl, lower alkoxy, cycloalkyl-lower alkoxy (optionally contg. a heteroatom in the ring), aryloxy, heteroaryloxy, etc.; or C and D are linked to each other to form a ring optionally contg. 1 or 2 O, N, or S atom(s); T = CO, C:S, SO, SO2, NHCO, NHCS; J, J' = H, halo, lower alkyl, lower alkoxy, NO2] are prepd. by the solid phase method using Wang resin. These compds. are useful for the treatment or prevention of inflammatory disease states related to the .alpha.4 integrin-dependent adhesion process, e.g. rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, multiple sclerosis, Sjogren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular diseases, atherosclerosis, restenosis, tumor proliferation, tumor metastasis, and transplant rejection. Thus, a soln. of Fmoc-Phe(4-NO2)-OH, 2,6-dichlorobenzoyl chloride, and pyridine in				

N-methylpyrrolidone was added to Wang resin and stirred at room temp. for 16 h to give Fmoc-Phe(4-NO₂)-Wang resin which was deprotected by 20% piperidine in DMF at room temp. for 15 min to afford H-Phe(4-NO₂)-Wang resin and then acylated by 2,6-dichlorobenzoyl chloride and 2,6-lutidine in N-methylpyrrolidone at room temp. for 16 h to give 2,6-dichlorobenzoyl-Phe(4-NO₂)-Wang resin. The latter compd.-bound resin was reduced by SnCl₂·2H₂O in EtOH/N-methylpyrrolidone at room temp. for 16 h to 2,6-dichlorobenzoyl-Phe(4-NH₂)-Wang resin which was cyclocondensed with Me 2-isocyanatobenzoate in N-methylpyrrolidone at room temp. for 16 h to give 2,6-dichlorobenzoyl-Phe(4-Q)-Wang resin (Q = 1,2,3,4-tetrahydroquinazolin-3-yl) and then methylated by Me iodide in the presence of 18-crown-6 ether and K₂CO₃ in N-methylpyrrolidone at room temp. for 3 days to give 2,6-dichlorobenzoyl-Phe(4-Q)-Wang resin (Q = 1-methyl-1,2,3,4-tetrahydroquinazolin-3-yl). Resin-cleavage reaction with 5% aq. CF₃CO₂H at room temp. for 1 h gave 2,6-dichlorobenzoyl-Phe(4-Q)-OH (Q = 1-methyl-1,2,3,4-tetrahydroquinazolin-3-yl) (II). II and 2-chloro-6-methylbenzoyl-Phe(4-Q)-OH (Q = 1-methyl-1,2,3,4-tetrahydroquinazolin-3-yl) inhibited the binding of human recombinant VCAM-1 to human T cell Jurikat (ATCC TIB-152) cell expressing integrin .alpha.4.beta.1 with IC₅₀ of 1.0 and 0.2 nM, resp.

IT 401904-99-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of novel phenylalanine derivs. having .alpha.4 integrin-inhibitory activity for prevention or treatment of inflammatory disease states related to the .alpha.4 integrin-dependent adhesion process)

RN 401904-99-2 CAPLUS

CN L-Phenylalanine, N-(2,6-dichlorobenzoyl)-4-[2-(2,2-dimethylhydrazino)-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:846593 CAPLUS

DN 136:256724

TI Peptide/benzodiazepine hybrids as ligands of CCKA and CCKB receptors

AU Escherich, Achim; Lutz, Jurgen; Escrieux, Chantal; Fourmy, Daniel; Van Neuren, A. Stephanie; Muller, Gerhard; Schafferhans, Andrea; Klebe, Gerhard; Moroder, Luis

CS Max-Planck Institute of Biochemistry, Martinsried, 82152, Germany

SO Biopolymers (2001), Volume Date 2000-2001, 56(2), 55-76

CODEN: BIPMAA; ISSN: 0006-3525

PB John Wiley & Sons, Inc.

DT Journal

LA English

AB The (neuro)hormones gastrin and cholecystokinin (CCK) share a common C-terminal tetrapeptide amide sequence that has been recognized as the message portion while the N-terminal extensions are responsible for the CCKA and CCKB receptor subtype selectivity and avidity. 1,4-Benzodiazepine derivs. are potent and selective antagonists of these receptors, and according to comparative mol. field anal., the structures of these nonpeptidic compds. could well mimic the message sequence of the peptide agonists at least in terms of spatial array of the arom. residues. Docking of a larger series of low mol. wt. nonpeptide antagonists to a homol. modeling derived CCKB receptor structure revealed a consensus binding mode that is further validated by data from site-directed mutagenesis studies of the receptors. Whether this putative binding pocket of the nonpeptide antagonists is identical to that of the message portion of the peptide agonists, or whether it is distinct and spatially sepd., or overlapping, but with.


IT 404391-53-3 404391-54-4

RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)

(peptide/benzodiazepine hybrids as ligands of CCKA and CCKB receptors)


RN 404391-53-3 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[4-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 404391-54-4 CAPLUS

CN Hydrazinecarboxamide, N-(4-bromophenyl)-2-[3,4-dihydro-3-[4-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RE.CNT 90 THERE ARE 90 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:571561 CAPLUS
 DN 131:310617
 TI Novel triazolo[4,3-a]quinazolinone and bis-triazolo[4,3-a:4,3'-c]quinazolines: synthesis and antitoxoplasmosis effect
 AU El-Tombary, Alaa A.; Ismail, Khadiga A.; Aboulwafa, Omaima M.; Omar, A.-Mohsen M. E.; El-Azzouni, Mervat Z.; El-Mansoury, Salwa T.
 CS Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Alexandria, Alexandria, 21215, Egypt
 SO Farmaco (1999), 54(7), 486-495
 CODEN: FPMCE8; ISSN: 0014-827X
 PB Elsevier Science S.A.
 DT Journal
 LA English
 OS CASREACT 131:310617
 AB Several quinazoline derivs. contg. substituted thiosemicarbazido and S-methylisothiosemicarbazido groups at the 2-position and at both the 2- and 4-positions were synthesized. Treatment of the S-methylthiosemicarbazides with morpholine or diethylamine did not give the corresponding guanidines. Instead, they underwent cyclodesulfurization into the condensed ring systems, [1,2,4]triazolo[4,3-a]quinazolinones and bis-[1,2,4]triazolo[4,3-a:4',3'-c]quinazolines. Evaluation of the products for antitoxoplasmosis effect by studying the ultrastructure morphol. of the organisms using SEM indicated their efficacy in causing structural deformity of Toxoplasma gondii. Such a deformity plays an important role in obstructing the entry of the organisms into host cells.
 IT 247257-82-5P 247257-84-7P 247257-85-8P
 247257-86-9P 247257-88-1P 247257-89-2P
 247257-90-5P 247257-91-6P 247257-92-7P
 247257-93-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and reactant for prepn. of triazolo[4,3-a]quinazolinones)
 RN 247257-82-5 CAPLUS
 CN Hydrazinecarbothioamide, 2-(1,4-dihydro-4-oxo-2-quinazolinyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 247257-84-7 CAPLUS
 CN Hydrazinecarbothioamide, 2-(1,4-dihydro-4-oxo-2-quinazolinyl)-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 247257-85-8 CAPLUS

CN Hydrazinecarbothioamide, 2-(1,4-dihydro-4-oxo-2-quinazolinyl)-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 247257-86-9 CAPLUS

CN Hydrazinecarboximidothioic acid, 2-(1,4-dihydro-4-oxo-2-quinazolinyl)-N-phenyl-, methyl ester (9CI) (CA INDEX NAME)




RN 247257-88-1 CAPLUS

CN Hydrazinecarboximidothioic acid, 2-(1,4-dihydro-4-oxo-2-quinazolinyl)-N-(4-methylphenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 247257-89-2 CAPLUS

CN Hydrazinecarboximidothioic acid, 2-(1,4-dihydro-4-oxo-2-quinazolinyl)-N-(4-methoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 247257-90-5 CAPLUS

CN Hydrazinecarboximidomethyl acid, 2-(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)-N-phenyl-, methyl ester (9CI) (CA INDEX NAME)




RN 247257-91-6 CAPLUS

CN Hydrazinecarboximidomethyl acid, N-(4-chlorophenyl)-2-(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 247257-92-7 CAPLUS


CN Hydrazinecarboximidomethyl acid, 2-(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)-N-(4-methylphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 247257-93-8 CAPLUS

CN Hydrazinecarboximidomethyl acid, 2-(3,4-dihydro-3-methyl-4-oxo-2-

quinazolinyl)-N-(4-methoxyphenyl)-, methyl ester (9CI) (CA INDEX NAME)




IT 247257-83-6P 247257-87-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (prepn. and reactant for prepn. of triazolo[4,3-a]quinazolinones and antitoxoplasmosis effect)


RN 247257-83-6 CAPLUS

CN Hydrazinecarbothioamide, N-(4-chlorophenyl)-2-(1,4-dihydro-4-oxo-2-quinazolinyl)- (9CI) (CA INDEX NAME)



RN 247257-87-0 CAPLUS

CN Hydrazinecarboximidethioic acid, N-(4-chlorophenyl)-2-(1,4-dihydro-4-oxo-2-quinazolinyl)-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1999:256025 CAPLUS

DN 130:325127

TI Synthesis and effect of some new [1,2,4]triazolo[4,3-a]quinazolin-5(4H)-ones and related compounds on Ehrlich ascites carcinoma cells

AU Ghorab, Moustafa M.; Abdel-Hamide, Sami G.; El-Gaby, Mohamed S. A.; El-Sayed, Sami M.

CS Department of Drug Radiation Research, National Center for Radiation Research and Technology, Nasr City, Egypt

SO Acta Pharmaceutica (Zagreb) (1999) 49(1), 1-10

CODEN: ACPHEE; ISSN: 1330-0075

PB Croatian Pharmaceutical Society

DT Journal

LA English


AB Synthesis of several new 7-iodo-4-phenyl-1-substituted-[1,2,4]triazolo[4,3-a]quinazolin-5(4H-ones) and related heterocycle compds., e.g., I, have been reported. The structures of newly prepd. compds. were confirmed by elemental anal., chem. reactions and spectral data. Benzopyrimidine II was among the most potent cytotoxic agents.

IT 223704-98-1P 223705-03-1P 223705-06-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (prepn., cytotoxicity, and carcinoma inhibitory activity of triazoloquinazolinones)


RN 223704-98-1 CAPLUS

CN Acetic acid, 2-(3,4-dihydro-6-iodo-4-oxo-3-phenyl-2-quinazolinyl)hydrazide (9CI) (CA INDEX NAME)




RN 223705-03-1 CAPLUS

CN Hydrazinecarboxylic acid, 2-(3,4-dihydro-6-iodo-4-oxo-3-phenyl-2-quinazolinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 223705-06-4 CAPLUS

CN Acetic acid, chloro-, 2-(3,4-dihydro-6-iodo-4-oxo-3-phenyl-2-quinazolinyl)hydrazide (9CI) (CA INDEX NAME)




IT 223705-01-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn., cytotoxicity, and carcinoma inhibitory activity of triazoloquinazolinones)


RN 223705-01-9 CAPLUS

CN Acetic acid, trifluoro-, 2-(3,4-dihydro-6-iodo-4-oxo-3-phenyl-2-quinazolinyl)hydrazide (9CI) (CA INDEX NAME)




RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:74169 CAPLUS
 DN 130:249317
 TI Effect of novel biologically active oxadiazino-, oxadiazolo-, and oxathiadiazolo-quinazolinones on non-irradiated and radio-resistant *Staphylococcus aureus*
 AU Abdel-Hamde, Sami G.; Ghorab, Moustafa M.; El-Hifnawi, Hala N.
 CS Pharmaceutical Chemistry Department Faculty of Pharmacy, Al-Azhar University, Nasr City, Egypt
 SO Acta Pharmaceutica (Zagreb) (1998), 48(4), 249-258
 CODEN: ACPHEE; ISSN: 1330-0075
 PB Croatian Pharmaceutical Society
 DT Journal
 LA English
 AB Searching for new antibacterial agents, some new quinazolinones contg. oxadiazino, oxadiazolo, and oxathiadiazolo moieties have been synthesized. The former structure of the new products was deduced from elemental anal. and spectral data. 6-Iodo-2 thioxo-1H-quinazolin-4(3H)-one, 8-iodo-2-oxo-5-phenyl-1H-[1,2,4]-oxadiazino-[4,3-a]-quinazolin-6(5H)-one (I), 8-iodo-5-phenyl-1,2-dihydro-[1,2,4]-oxadiazino-[4,3-a]-quinazolin-6(5H)-one (II), 7-iodo-4-phenyl-1-thioxo-[1,2,4]-oxadiazolo-[4,3-l]-quinazolin-5(4)-one (III), 6-iodo-2-(benzoyl)oxime-3-phenyl-1H-quinazolin-4(3H)-one (IV) and 6-iodo-2-(phenacyl)oxime-3-phenyl-1H-quinazolin-4(3H)-one showed a remarkable activity against the growth of non-irradiated *Staphylococcus aureus*, while the compd. II exhibited higher activity against radioresistant *Staphylococcus aureus*.
 IT 221657-74-5P 221657-82-5P 221657-88-1P 221657-99-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (synthesis and antibacterial activity testing of novel active oxadiazino-, oxadiazolo-, and oxathiadiazolo-quinazolinones on non-irradiated and radio-resistant *Staphylococcus aureus*)
 RN 221657-74-5 CAPLUS
 CN 2,4(1H,3H)-Quinazolin-6-one, 6-iodo-3-phenyl-, 2-[O-(ethoxycarbonyl)oxime] (9CI) (CA INDEX NAME)




RN 221657-82-5 CAPLUS
 CN Acetic acid, [[[3,4-dihydro-6-iodo-4-oxo-3-phenyl-2-quinazolinyl)amino]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 221657-88-1 CAPLUS

CN Acetic acid, [[[3,4-dihydro-6-iodo-4-oxo-3-phenyl-2-quinazolinyl)amino]oxy]- (9CI) (CA INDEX NAME)



RN 221657-99-4 CAPLUS

CN Acetic acid, [[[3,4-dihydro-6-iodo-4-oxo-3-phenyl-2-quinazolinyl)amino]oxy]oxo-, ethyl ester (9CI) (CA INDEX NAME)




IT **221657-64-3P 221658-07-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(synthesis and antibacterial activity testing of novel active oxadiazino-, oxadiazolo-, and oxathiadiazolo-quinazolinones on non-irradiated and radio-resistant Staphylococcus aureus)

RN 221657-64-3 CAPLUS


CN 2,4(1H,3H)-Quinazolin-2-one, 6-iodo-3-phenyl-, 2-[O-(chloroacetyl)oxime] (9CI) (CA INDEX NAME)




RN 221658-07-7 CAPLUS
 CN 2,4(1H,3H)-Quinazolin-4-one, 6-iodo-3-phenyl-, 2-(O-acetyloxime) (9CI)
 (CA INDEX NAME)



IT **221658-09-9P 221658-10-2P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (synthesis and antibacterial activity testing of novel active oxadiazino-, oxadiazolo-, and oxathiadiazolo-quinazolinones on non-irradiated and radio-resistant Staphylococcus aureus)
 RN 221658-09-9 CAPLUS
 CN 2,4(1H,3H)-Quinazolin-4-one, 6-iodo-3-phenyl-, 2-(O-benzoyloxime) (9CI)
 (CA INDEX NAME)



RN 221658-10-2 CAPLUS
 CN 2,4(1H,3H)-Quinazolin-4-one, 6-iodo-3-phenyl-, 2-[O-(phenylacetyl)oxime] (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:169718 CAPLUS

DN 128:238969

TI Novel Nonpeptide CCK-B Antagonists: Design and Development of Quinazolinone Derivatives as Potent, Selective, and Orally Active CCK-B Antagonists

AU Padia, Janak K.; Field, Mark; Hinton, Joanna; Meecham, Ken; Pablo, Julius; Pinnock, Rob; Roth, Bruce D.; Singh, Lakhbir; Suman-Chauhan, Nirmala; Trivedi, Bharat K.; Webdale, Louise

CS Departments of Chemistry and of Pharmacokinetics and Drug Metabolism, Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company, Ann Arbor, MI, 48105, USA

SO Journal of Medicinal Chemistry (1998), 41(7), 1042-1049
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

AB Urea-linked quinazolines [I; R = (un)substituted Ph, cyclohexyl; R1 = (un)substituted Ph, 3-pyridyl, 1-naphthyl] were prepd. as selective orally active CCK-B antagonists. Thus, thioxoquinazolinones II (prepd. from anthranilic acid and the requisite isothiocyanate) were treated with hydrazine gave the 2-hydrazino compds. which were then treated with an isocyanate to give I. Representative compds. of this series were tested in the functional assay, i.e., guinea pig stomach strip assay, and showed pure antagonist profiles. I [R = 3-(tert-butoxycarbonyl)phenyl, R1 = 3-isopropoxyphenyl] and I [R = 3-cyanophenyl, R1 = 3-(dimethylamino)phenyl] (III) were orally active in the elevated rat X-maze test and showed dose-dependent anxiolytic-like action. These compds. were also evaluated for their pharmacokinetic profile. The abs. oral bioavailability of III was 22% in rats.

IT 180423-04-5P 180423-05-6P 180423-06-7P

180423-07-8P 180423-08-9P 180423-09-0P

180423-10-3P 180423-11-4P 180423-13-6P

180423-14-7P 180423-15-8P 180423-16-9P

180423-17-0P 180423-18-1P 180423-21-6P

180423-22-7P 180423-23-8P 180423-24-9P

180423-25-0P 180423-26-1P 180423-27-2P

180423-29-4P 180423-32-9P 180423-33-0P

180423-34-1P 180423-35-2P 180423-36-3P

180423-37-4P 180423-38-5P 180423-39-6P

180423-41-0P 180423-44-3P 180423-45-4P

180423-46-5P 205063-57-6P 205063-59-8P

205063-61-2P 205063-64-5P 205063-66-7P

205063-71-4P 205063-80-5P 205063-88-3P

205063-98-5P 205064-08-0P 205064-19-3P

205064-22-8P 205064-24-0P 205064-27-3P

205064-29-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of urea-linked quinazolinones as selective CCK-B receptor antagonists)

RN 180423-04-5 CAPLUS


CN Hydrazinecarboxamide, N-(4-bromophenyl)-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)

not paid.
Applicant's Publ.




RN 180423-05-6 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-06-7 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 180423-07-8 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 180423-08-9 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 180423-09-0 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 180423-10-3 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 180423-11-4 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-13-6 CAPLUS

CN Benzoic acid, 4-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-14-7 CAPLUS

CN Benzoic acid, 2-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-15-8 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 180423-16-9 CAPLUS

CN Hydrazinecarboxamide, N-(4-chlorophenyl)-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 180423-17-0 CAPLUS

CN Hydrazinecarboxamide, N-(3-cyanophenyl)-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 180423-18-1 CAPLUS


CN Hydrazinecarboxamide, N-cyclohexyl-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 180423-21-6 CAPLUS


CN Benzoic acid, 3-[[[2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-

quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-22-7 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(3,4-dichlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-23-8 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(3-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-24-9 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(1-naphthalenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-25-0 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-3-(3-methoxyphenyl)-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-26-1 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(3-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-27-2 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(dimethylamino)phenyl]-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-29-4 CAPLUS

CN Benzoic acid, 3-[[[2-[[3,4-dihydro-4-oxo-3-(3-pyridinyl)-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-32-9 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-33-0 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(3,4-dichlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-34-1 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(3-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-35-2 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-(1-naphthalenyl)-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-36-3 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-(3-methoxyphenyl)-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-37-4 CAPLUS

CN Hydrazinecarboxamide, 2-[3-[3-(dimethylamino)phenyl]-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-38-5 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-4-oxo-3-(3-pyridinyl)-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-39-6 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(3-aminophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-41-0 CAPLUS

CN Hydrazinecarboxamide, N-(3-cyanophenyl)-2-[3-[3-(dimethylamino)phenyl]-3,4-dihydro-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 180423-44-3 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-45-4 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(3,4-dimethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-46-5 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(3,4-dimethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 205063-57-6 CAPLUS

CN Benzoic acid, 4-bromo-, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazide (9CI) (CA INDEX NAME)




RN 205063-59-8 CAPLUS

CN Hydrazinecarboxamide, 2-(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 205063-61-2 CAPLUS

CN Hydrazinecarboxamide, 2-(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 205063-64-5 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(3-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 205063-66-7 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(2,3-dichlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 205063-71-4 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(3-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 205063-80-5 CAPLUS

CN Benzoic acid, 3-[[[2-(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 205063-88-3 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(2,3-dichlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 205063-98-5 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(3-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 205064-08-0 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 205064-19-3 CAPLUS

CN Hydrazinecarboxamide, N-(3-chlorophenyl)-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 205064-22-8 CAPLUS


CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 205064-24-0 CAPLUS


CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-

quinazolinyl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 205064-27-3 CAPLUS

CN Hydrazinecarboxamide, N-(3-cyanophenyl)-2-(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)- (9CI) (CA INDEX NAME)



RN 205064-29-5 CAPLUS

CN Hydrazinecarboxamide, N-(3-cyanophenyl)-2-[3-(3-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1996:527667 CAPLUS

DN 125:168015

TI Preparation of quinazolinones as cholecystokinin (CCK) antagonists

IN Padia, Janak Khimchand

PA Warner-Lambert Company, USA

SO PCT Int. Appl., 18 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9620178	A1	19960704	WO 1995-US15918	19951206
	W: CA, EE, JP, LT, LV, MX, SI				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

PRAI	US 1994-364624	19941227	} Parent.
	US 1995-545241	19951121	

OS MARPAT 125:168015

AB The title compds. [I; W, X, Y, Z = (substituted) CH, N and no more than two of them are N; M = O, S; A = (N-substituted) NHCO(CH₂)_n, NHCOO(CH₂)₂, NHCONH(CH₂)_n, etc.; R₁, R₂ = C1-6 alkyl, (substituted) Ph, heteroaryl, etc.; n = 0-1] with good binding affinity for the CCK-A and CCK-B receptors and useful to suppress appetite, reduce gastric acid secretion and anxiety, to treat gastrointestinal ulcers, psychosis and pain, and to block drug or alc. withdrawal reaction, were prep'd. Thus, reaction of hydrazine II with 4-BrC₆H₄NCO in MeCN afforded 47% I [W, X, Y, Z = CH; M = O; A = NHCONH; R₁ = 4-BrC₆H₄; R₂ = 3-iPrOC₆H₄] which showed K_i of 3432 nM against CCK-A and 16.0 nM against CCK-B.


IT 180423-10-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of quinazolinones as cholecystokinin (CCK) antagonists)

RN 180423-10-3 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)



Elected Species.


IT 180423-04-5P 180423-05-6P 180423-06-7P
 180423-07-8P 180423-08-9P 180423-09-0P
 180423-11-4P 180423-12-5P 180423-13-6P
 180423-14-7P 180423-15-8P 180423-16-9P
 180423-17-0P 180423-18-1P 180423-19-2P
 180423-20-5P 180423-21-6P 180423-22-7P

180423-23-8P 180423-24-9P 180423-25-0P
 180423-26-1P 180423-27-2P 180423-28-3P
 180423-29-4P 180423-30-7P 180423-31-8P
 180423-32-9P 180423-33-0P 180423-34-1P
 180423-35-2P 180423-36-3P 180423-37-4P
 180423-38-5P 180423-39-6P 180423-41-0P
 180423-42-1P 180423-43-2P 180423-44-3P
 180423-45-4P 180423-46-5P 180423-47-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of quinazolinones as cholecystokinin (CCK) antagonists)


RN 180423-04-5 CAPLUS

CN Hydrazinecarboxamide, N-(4-bromophenyl)-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 180423-05-6 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-06-7 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 180423-07-8 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 180423-08-9 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 180423-09-0 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 180423-11-4 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-12-5 CAPLUS

CN Hydrazinecarboxamide, N-(2,6-dichloro-4-pyridinyl)-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 180423-13-6 CAPLUS

CN Benzoic acid, 4-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-14-7 CAPLUS

CN Benzoic acid, 2-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-15-8 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 180423-16-9 CAPLUS

CN Hydrazinecarboxamide, N-(4-chlorophenyl)-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 180423-17-0 CAPLUS

CN Hydrazinecarboxamide, N-(3-cyanophenyl)-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 180423-18-1 CAPLUS

CN Hydrazinecarboxamide, N-cyclohexyl-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 180423-19-2 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-20-5 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(2-ethylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-21-6 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-22-7 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(3,4-dichlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-23-8 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(3-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-24-9 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-3-(1-naphthalenyl)-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-25-0 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-3-(3-methoxyphenyl)-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-26-1 CAPLUS

CN Benzoic acid, 3-[[[2-[3-(3-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)





RN 180423-27-2 CAPLUS

CN Benzoic acid, 3-[[[2-[3-[3-(dimethylamino)phenyl]-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-28-3 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-3-[4-(4-morpholinylsulfonyl)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-29-4 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-4-oxo-3-(3-pyridinyl)-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 180423-30-7 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-31-8 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(2-ethylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-32-9 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-33-0 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(3,4-dichlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-34-1 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(3-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-35-2 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-(1-naphthalenyl)-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-36-3 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-(3-methoxyphenyl)-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-37-4 CAPLUS

CN Hydrazinecarboxamide, 2-[3-[3-(dimethylamino)phenyl]-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-38-5 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-4-oxo-3-(3-pyridinyl)-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-39-6 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(3-aminophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 180423-41-0 CAPLUS

CN Hydrazinecarboxamide, N-(3-cyanophenyl)-2-[3-[3-(dimethylamino)phenyl]-3,4-dihydro-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 180423-42-1 CAPLUS

CN Hydrazinecarboxamide, N-(3-cyanophenyl)-2-[3,4-dihydro-4-oxo-3-(3-pyridinyl)-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 180423-43-2 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-[3-(dimethylamino)phenyl]-, (9CI) (CA INDEX NAME)




RN 180423-44-3 CAPLUS

CN Benzoic acid, 3-[[[2-[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 180423-45-4 CAPLUS


CN Benzoic acid, 3-[[[2-[3-(3,4-dimethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 180423-46-5 CAPLUS


CN Hydrazinecarboxamide, 2-[3-(3,4-dimethoxyphenyl)-3,4-dihydro-4-oxo-2-

quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 180423-47-6 CAPLUS

CN Hydrazinecarboxamide, N-(3-cyanophenyl)-2-[3-(3,4-dimethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)



L15 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1996:122150 CAPLUS

DN 124:289415

TI Synthesis and biological activities of some new 1-thioxo-4-aryl-s-triazolo[4,3-a]quinazolin-5-ones

AU Reddy, P. C. S.; Reddy, Ch. K.; Reddy, K. Kondal; Reddy, V. M.

CS Department Chemistry, Osmania University, Hyderabad, 500 007, India

SO Indian Journal of Heterocyclic Chemistry (1995), 5(2), 129-34

CODEN: IJCHEI; ISSN: 0971-1627

PB Lucknow University, Dep. of Chemistry

DT Journal

LA English

AB 2-Thioxo-3-arylquinazolin-4(3H)-ones have been obtained from anthranilic acid and aryl isothiocyanates. Methylation with Me iodide in ethanolic sodium hydroxide afforded the corresponding 2-methylthio-3-arylquinazolin-4(3H)-ones which on heating with excess hydrazine hydrate yielded 2-hydrazino-3-arylquinazolin-4(3H)-ones. The hydrazino compds. have been converted into 1-(3-aryl-4-oxoquinazolin-2-yl)-4-aryl-3-thiosemicarbazides (I) by their condensation with appropriate aryl isothiocyanates. Cyclization of I gave 1-thioxo-4-aryl-s-triazolo[4,3-a]quinazolin-5-one (II). The 1-thioxo compds. II on desulfurization afforded 4-aryl-s-triazolo[4,3-a]quinazolin-5-ones. The title compds. have been screened for their antimicrobial, analgesic and antiinflammatory activities by std. methods and a few of them were active.


IT 77437-17-3P 175688-61-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and cyclization of)

RN 77437-17-3 CAPLUS


CN Hydrazinecarbothioamide, N-(4-bromophenyl)-2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)



*not included
in the claims*

RN 175688-61-6 CAPLUS

CN Hydrazinecarbothioamide, 2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




IT 67443-03-2P 67443-09-8P 175688-57-0P

175688-58-1P 175688-59-2P 175688-60-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (prepn., cyclization and antimicrobial activity of)


RN 67443-03-2 CAPLUS

CN Hydrazinecarbothioamide, 2-(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 67443-09-8 CAPLUS

CN Hydrazinecarbothioamide, 2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 175688-57-0 CAPLUS

CN Hydrazinecarbothioamide, N-(4-chlorophenyl)-2-(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)- (9CI) (CA INDEX NAME)




RN 175688-58-1 CAPLUS

CN Hydrazinecarbothioamide, N-(4-bromophenyl)-2-(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)- (9CI) (CA INDEX NAME)




RN 175688-59-2 CAPLUS

CN Hydrazinecarbothioamide, 2-(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 175688-60-5 CAPLUS


CN Hydrazinecarbothioamide, N-(4-chlorophenyl)-2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




L15 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:55402 CAPLUS
DN 116:55402
TI Novel 1,2,4-triazolo[4,3-a]quinazolinones as potential antimicrobial and antihistaminic agents
AU Omar, A. Mohsen M. E.; El-Din, Shams A. Shams; Labouta, Ibrahim M.; El-Tombary, Alaa A.
CS Fac. Pharm., Univ. Alexandria, Alexandria, Egypt
SO Alexandria Journal of Pharmaceutical Sciences (1991), 5(1), 94-8
CODEN: AJPSES; ISSN: 1110-1792
DT Journal
LA English
AB Several triazolo[4,3-a]quinazolinones, bearing in the 1-position variously substituted thiadiazole rings, were synthesized. Some of the products displayed a moderate antimicrobial activity and the preliminary testing of 2 products for antihistaminic properties indicated significant activity.
IT **138597-70-3DP**, derivs.
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and microbicidal and antihistaminic activity of)
RN 138597-70-3 CAPLUS
CN Hydrazinecarbothioamide, 2-(1,4-dihydro-4-oxo-2-quinazolinyl)- (9CI) (CA INDEX NAME)




L15 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1989:452455 CAPLUS
 DN 111:52455
 TI Synthesis and pesticidal activity of some quinazolin-4(3H)-one derivatives
 AU Gupta, Anil K. Sen; Pandey, Ashok Kumar
 CS Dep. Chem., Lucknow Univ., Lucknow, 226007, India
 SO Pesticide Science (1989), 26(1), 41-9
 CODEN: PSSCBG; ISSN: 0031-613X
 DT Journal
 LA English
 AB A no. of quinazolin-4(3H)-one carbothioamides, pyrazoles, pyrazolones and tetrazole derivs. have been synthesized by the reaction of 2-hydrazino-3-(4-substituted phenyl)-quinazolin-4(3H)-ones with the appropriate aryl isothiocyanate, acetyl acetone, Et acetoacetate and nitrous acid. All the compds. were tested in vitro for antibacterial, insecticidal and antifungal activity and found to have some activity.
 IT 121661-90-3P 121661-91-4P 121661-92-5P
 121661-93-6P 121661-94-7P 121661-95-8P
 121661-96-9P 121661-97-0P 121661-98-1P
 121661-99-2P 121662-00-8P 121662-01-9P
 121678-90-8P
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and insecticidal activity of)
 RN 121661-90-3 CAPLUS
 CN Hydrazinecarbothioamide, 2-(6-bromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 121661-91-4 CAPLUS
 CN Hydrazinecarbothioamide, 2-(6-bromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 121661-92-5 CAPLUS
 CN Hydrazinecarbothioamide, 2-(6-bromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-(4-bromophenyl)- (9CI) (CA INDEX NAME)




RN 121661-93-6 CAPLUS

CN Hydrazinecarbothioamide, 2-[6-bromo-3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 121661-94-7 CAPLUS

CN Hydrazinecarbothioamide, 2-[6-bromo-3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 121661-95-8 CAPLUS

CN Hydrazinecarbothioamide, 2-[6-bromo-3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]-N-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 121661-96-9 CAPLUS

CN Hydrazinecarbothioamide, 2-[6-bromo-3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 121661-97-0 CAPLUS

CN Hydrazinecarbothioamide, 2-[6-bromo-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]-N-(4-bromophenyl)- (9CI) (CA INDEX NAME)




RN 121661-98-1 CAPLUS

CN Hydrazinecarbothioamide, 2-[6-bromo-3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 121661-99-2 CAPLUS

CN Hydrazinecarbothioamide, 2-[6-bromo-3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 121662-00-8 CAPLUS

CN Hydrazinecarbothioamide, 2-[6-bromo-3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 121662-01-9 CAPLUS

CN Hydrazinecarbothioamide, 2-[6-bromo-3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(4-bromophenyl)- (9CI) (CA INDEX NAME)





RN 121678-90-8 CAPLUS


CN Hydrazinecarbothioamide, 2-[6-bromo-3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




L15 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1988:630936 CAPLUS
 DN 109:230936
 TI Guanidine-annelated heterocycles. X. Synthesis of 1-(acetylamino)-1H,5H-1,2,4-triazolo[3,2-b]quinazolin-5-one derivatives
 AU Liu, Kang Chien; Hsu, Shang Wei
 CS Sch. Pharm., Natl. Def. Med. Cent., Taipei, Taiwan
 SO Taiwan Yaoxue Zazhi (1987), 39(1), 54-6
 CODEN: JTPHAO; ISSN: 0368-4520
 DT Journal
 LA English
 AB Acetylation of aminohydrazinoquinazolinone I (R = H) gave 95% I (R = Ac). Subsequent cyclocondensation reactions of I (R = Ac) with HC(OEt)₃ and ClCO₂Et gave (acetylamino)triazoloquinazolinones II (R₁ = H, OH) resp.
 IT **117586-88-6P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and cyclocondensation reactions of, with tri-Et orthoformate and Et chloroformate)
 RN 117586-88-6 CAPLUS
 CN Acetic acid, 2-(3-amino-3,4-dihydro-4-oxo-2-quinazolinyl)hydrazide (9CI)
 (CA INDEX NAME)



L15 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1985:422540 CAPLUS
 DN 103:22540
 TI Synthesis of compounds with aminoguanidine structure. 11. Synthesis of
 some new s-triazolo[3,4-b]quinazolin-5(10H)-ones
 AU Kottke, K.; Kuehmstedt, H.
 CS Sekt. Pharm., Ernst-Moritz-Arndt-Univ., Greifswald, DDR-2200, Ger. Dem.
 Rep.
 SO Pharmazie (1984), 39(12), 868-9
 CODEN: PHARAT; ISSN: 0031-7144
 DT Journal
 LA German
 OS CASREACT 103:22540
 AB 2-RNHC6H4CO2H (R = Me, Et) was cyclocondensed with NH4SCN to give
 thioxoquinazolinone I which underwent hydrazinolysis to give
 2-hydrazino-4(3H)-quinazolinone II (R1 = R2 = H). The latter was
 cyclocondensed with a variety of reactants to give triazolo[3,4-
 b]quinazolin-5(10H)-ones III (R3 = H, Me, SH, EtO2CCH2). II (R1 = R2 = H)
 was condensed with R4NCO (R4 = Ph, 1-naphthyl) and with cyclohexanone to
 give II (R1 = H, R2 = CONHR4; R1R2 = cyclohexylidene), resp.
 IT **91511-22-7P 91511-23-8P 91511-24-9P**
91511-25-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 91511-22-7 CAPLUS
 CN Hydrazinecarboxamide, 2-(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)-N-
 phenyl- (9CI) (CA INDEX NAME)




RN 91511-23-8 CAPLUS
 CN Hydrazinecarboxamide, 2-(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)-N-1-
 naphthalenyl- (9CI) (CA INDEX NAME)




RN 91511-24-9 CAPLUS
 CN Hydrazinecarboxamide, 2-(1-ethyl-1,4-dihydro-4-oxo-2-quinazolinyl)-N-

phenyl- (9CI) (CA INDEX NAME)



RN 91511-25-0 CAPLUS

CN Hydrazinecarboxamide, 2-(1-ethyl-1,4-dihydro-4-oxo-2-quinazolinyl)-N-1-naphthalenyl- (9CI) (CA INDEX NAME)



L15 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1984:490970 CAPLUS

DN 101:90970

TI 5-Oxo-5H,10H-s-triazolo[3,4-b]quinazolines

IN Kottke, Karl; Kuehmstedt, Hans; Wehlan, Helmut; Landmann, Hellmut

PA Akademie der Wissenschaften der DDR, Ger. Dem. Rep.

SO Ger. (East), 14 pp.

CODEN: GEXXA8

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DD 206555	A1	19840201	DD 1982-237905	19820305
PRAI	DD 1982-237905		19820305		

AB The title compds. [I; R = H, alkyl, alkoxy, alkylthio, OH, SH; R1 = alkyl, (un)substituted aryl; R2 = H, alkoxy, alkylthio, alkylsulfonyl, amino, thiocyanato, OH, SH, (un)substituted alkyl, aryl] were prepd. by cyclocondensation of hydrazinoquinazolinones II with carboxylic acid derivs., e.g. R2CO2H. Thus, II (R = H, R1 = Et) was refluxed with CH2(CO2Et)2 to give 73% I (R = H, R1 = Et, R2 = CH2CO2Et).


IT 91511-22-7P 91511-23-8P 91511-24-9P

91511-25-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)


RN 91511-22-7 CAPLUS

CN Hydrazinecarboxamide, 2-(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 91511-23-8 CAPLUS

CN Hydrazinecarboxamide, 2-(1,4-dihydro-1-methyl-4-oxo-2-quinazolinyl)-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 91511-24-9 CAPLUS

CN Hydrazinecarboxamide, 2-(1-ethyl-1,4-dihydro-4-oxo-2-quinazolinyl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 91511-25-0 CAPLUS

CN Hydrazinecarboxamide, 2-(1-ethyl-1,4-dihydro-4-oxo-2-quinazolinyl)-N-1-naphthalenyl- (9CI) (CA INDEX NAME)



L15 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1983:594989 CAPLUS

DN 99:194989

TI Triazoloquinazolones and their salts, intermediates for preparing them, their use as medicines and compositions containing them

IN Tully, Wilfred Roger; Westwood, Robert; Rowlands, David Alun; Clements-Jewery, Stephen

PA Roussel-UCLAF, Fr.

SO Eur. Pat. Appl., 39 pp.

CODEN: EPXXDW

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 76199	A2	19830406	EP 1982-401697	19820920
	EP 76199	A3	19840321		
	EP 76199	B1	19861230		
	R: AT, BE, CH, DE, FR, IT, LI, LU, NL, SE				
	IL 66835	A1	19880531	IL 1982-66835	19820917
	ZA 8206891	A	19831026	ZA 1982-6891	19820920
	AT 24509	E	19870115	AT 1982-401697	19820920
	US 4472400	A	19840918	US 1982-420798	19820921
	DK 8204206	A	19830325	DK 1982-4206	19820922
	DK 160308	B	19910225		
	DK 160308	C	19910729		
	AU 8288623	A1	19830331	AU 1982-88623	19820922
	AU 554959	B2	19860911		
	FI 8203278	A	19830325	FI 1982-3278	19820923
	FI 73435	B	19870630		
	FI 73435	C	19871009		
	GB 2108495	A1	19830518	GB 1982-27126	19820923
	GB 2108495	B2	19850724		
	ES 515904	A1	19831016	ES 1982-515904	19820923
	CA 1193597	A1	19850917	CA 1982-412016	19820923
	JP 58065292	A2	19830418	JP 1982-165197	19820924
	JP 03022389	B4	19910326		
	HU 26739	O	19830928	HU 1982-3090	19820924
	HU 186975	B	19851028		
PRAI	GB 1981-28875		19810924		
	EP 1982-401697		19820920		

OS CASREACT 99:194989

AB Triazoloquinazolones I [R, R1 = H, halo, alkyl, alkoxy, NO2; R2 = alkyl, cycloalkyl, aryl, aralkyl; R3 = amino; X = (CH2)1-31, CHMe] were prep'd. Thus, 2-H2NC6H4CO2Me was treated with PrNCO to give 2-MeO2CC6H4NHCONHPr which was cyclized to 3-propyl-2,4-quinazolinedione. Enol chlorination of the dione and reaction with N2H4 gave 2-hydrazino-3-propyl-4-quinazolinone which was cyclized with ClCH2COCl to give I (R = R1 = H, R2 = Pr, R3 = Cl, X = CH2). Amination of the latter comp'd. gave I (R = R1 = H, R2 = Pr, R3 = piperidino, X = CH2) which had a ED50 of 0.12 mg/kg i.v. against histamine-induced bronchial spasms in guinea pigs.

IT 86662-55-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and cyclization of)

RN 86662-55-7 CAPLUS

CN Propanoic acid, 3-chloro-, 2-[3,4-dihydro-4-oxo-3-(2-propenyl)-2-quinazolinyl]hydrazide (9CI) (CA INDEX NAME)

08/812,508



L15 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1983:198151 CAPLUS

DN 98:198151

TI Synthesis of compounds with aminoguanidine structure. Part 8.
1,4,7,9-Substituted 4,5-dihydro-s-triazolo[4,3-a]quinazolin-5-ones and
4,5-dihydrotetrazolo[1,5-a]quinazolin-5-ones

AU Kottke, K.; Kuehmstedt, H.; Knoke, D.

CS Sekt. Pharm., Ernst-Moritz-Arndt-Univ., Greifswald, Ger. Dem. Rep.

SO Pharmazie (1983), 38(1), 25-8

CODEN: PHARAT; ISSN: 0031-7144

DT Journal

LA German

OS CASREACT 98:198151

AB Triazoloquinazolinones I [R1 = Me, MeO, BuO, Cl, Br, 4-F, isoamyloxy, Me2;
R2 = H, Cl, Br; R3 = H, Br; X = CH, CMe, COH, CSR4 (R4 = H, Et, Pr), CNH2,
CCH2Cl, CPh, CCH2CO2Et, etc.] and tetrazoloquinazolinones I [R1 = BuO,
Me2, H; R2 = H, Cl, Br; R3 = H, Cl; X = N] were prepd. by reaction of
hydrazinoquinazolinones II with carboxylic acids, alkanoyl chlorides,
COCl2, CSCl2, BrCN, and dialkyl alkanedicarboxylates.

IT 77066-23-0P 85773-43-9P 85773-44-0P


85773-51-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(prepn. and cyclocondensation of, triazoloquinazolinone deriv. by)


RN 77066-23-0 CAPLUS

CN Hydrazinecarbothioamide, 2-[3-(2,4-dimethylphenyl)-3,4-dihydro-4-oxo-2-
quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 85773-43-9 CAPLUS

CN Hydrazinecarbothioamide, 2-(6-bromo-3,4-dihydro-4-oxo-3-phenyl-2-
quinazolinyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 85773-44-0 CAPLUS

CN Hydrazinecarbothioamide, 2-(6-chloro-3,4-dihydro-4-oxo-3-phenyl-2-
quinazolinyl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 85773-51-9 CAPLUS

CN Hydrazinecarbothioamide, 2-[6-bromo-3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)



IT 77066-21-8P 77747-37-6P 77747-38-7P

77747-39-8P 77775-32-7P 85773-09-7P

85773-10-0P 85773-11-1P 85773-38-2P

85773-39-3P 85773-40-6P 85773-41-7P

85773-42-8P 85773-45-1P 85773-46-2P

85773-47-3P 85773-48-4P 85773-49-5P


85773-50-8P 85773-52-0P 85773-53-1P

85773-54-2P 85773-55-3P 85784-60-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)


RN 77066-21-8 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(2,3-dimethylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 77747-37-6 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 77747-38-7 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 77747-39-8 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 77775-32-7 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 85773-09-7 CAPLUS

CN Butanoic acid, 2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazide (9CI) (CA INDEX NAME)




RN 85773-10-0 CAPLUS

CN Pentanoic acid, 2-[3-(4-methylphenyl)-4-oxo-2-quinazolinyl]hydrazide (9CI) (CA INDEX NAME)



RN 85773-11-1 CAPLUS


CN Pentanoic acid, 2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]hydrazide (9CI) (CA INDEX NAME)



RN 85773-38-2 CAPLUS


CN Hydrazinecarboxamide, 2-(6-bromo-3,4-dihydro-4-oxo-3-phenyl-2-

quinazolinyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 85773-39-3 CAPLUS

CN Hydrazinecarboxamide, 2-(6,8-dibromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 85773-40-6 CAPLUS

CN Hydrazinecarboxamide, 2-(6-chloro-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 85773-41-7 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(4-butoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 85773-42-8 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[4-(3-methylbutoxy)phenyl]-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 85773-45-1 CAPLUS

CN Hydrazinecarbothioamide, 2-(6,8-dibromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 85773-46-2 CAPLUS

CN Hydrazinecarbothioamide, 2-[3-(4-butoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 85773-47-3 CAPLUS

CN Hydrazinecarbothioamide, 2-[3,4-dihydro-3-[4-(3-methylbutoxy)phenyl]-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 85773-48-4 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(4-butoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 85773-49-5 CAPLUS

CN Hydrazinecarboxamide, 2-[6-bromo-3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 85773-50-8 CAPLUS

CN Hydrazinecarboxamide, 2-[6-bromo-3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 85773-52-0 CAPLUS

CN Hydrazinecarboxamide, 2-[3,4-dihydro-3-[4-(3-methylbutoxy)phenyl]-4-oxo-2-quinazolinyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 85773-53-1 CAPLUS

CN Hydrazinecarboxamide, 2-(6-chloro-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 85773-54-2 CAPLUS

CN Hydrazinecarboxamide, 2-(6-bromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 85773-55-3 CAPLUS

CN Hydrazinecarboxamide, 2-(6,8-dibromo-3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-1-naphthalenyl- (9CI) (CA INDEX NAME)



RN 85784-60-7 CAPLUS


CN Butanoic acid, 2-[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]hydrazide (9CI) (CA INDEX NAME)




L15 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1982:69016 CAPLUS
 DN 96:69016
 TI 1-Substituted 4-aryl-s-triazolo[4,3-a]quinazolin-5-ones
 IN Kottke, Karl; Kuehmstedt, Hans; Hagen, Volker; Renner, Helga; Schnitzler, Stephan
 PA Akademie der Wissenschaften der DDR, Institut fuer Werkstofforschung, Ger. Dem. Rep.
 SO Ger. (East), 21 pp.
 CODEN: GEXXA8
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DD 139715	Z	19800116	DD 1978-208205	19780929
PRAI	DD 1978-208205		19780929		

AB Anaphylaxis inhibitors I [R = H, Me, MeO, EtO, F, Cl, Br, Iodo; R1 = H, Me, (CH₂)_nCO₂Et (n = 0-2), OH, SH, alkyl, SCN] were prepd. from the hydrazinoquinazolines II. Thus, II (R = H) was cyclized with HC(OEt)₃ to give 83% I (R = R1 = H). At 3 .times. 10-5 mol/kg, I (R = m-Br, R1 = OH) gave 90% inhibition in the passive cutaneous anaphylaxis test.
 IT **67443-03-2P 67443-04-3P 67443-05-4P**
67443-06-5P 67443-07-6P 67443-08-7P
67443-09-8P 67443-10-1P 67443-11-2P
67443-12-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 67443-03-2 CAPLUS
 CN Hydrazinecarbothioamide, 2-(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 67443-04-3 CAPLUS
 CN Hydrazinecarbothioamide, 2-[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 67443-05-4 CAPLUS

CN Hydrazinecarbothioamide, 2-[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 67443-06-5 CAPLUS

CN Hydrazinecarbothioamide, 2-[3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 67443-07-6 CAPLUS

CN Hydrazinecarbothioamide, 2-[3-(2-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 67443-08-7 CAPLUS

CN Hydrazinecarbothioamide, 2-[3-(3-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 67443-09-8 CAPLUS

CN Hydrazinecarbothioamide, 2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 67443-10-1 CAPLUS

CN Hydrazinecarbothioamide, 2-[3,4-dihydro-3-(2-methoxyphenyl)-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 67443-11-2 CAPLUS


CN Hydrazinecarbothioamide, 2-[3,4-dihydro-3-(3-methoxyphenyl)-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




08/812,508

RN 67443-12-3 CAPLUS


CN Hydrazinecarbothioamide, 2-[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




L15 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1981:407198 CAPLUS
 DN 95:7198
 TI Iodine-substituted 2-hydrazino-3-phenylquinazol-4-ones and their cyclization products. Part 6. Synthesis of compounds with an aminoguanidine structure
 AU Kottke, K.; Kuehmstedt, H.
 CS Sekt. Pharm., Ernst-Moritz-Arndt-Univ. Greifswald, Greifswald, DDR-2200, Ger. Dem. Rep.
 SO Pharmazie (1980), 35(12), 800-1
 CODEN: PHARAT; ISSN: 0031-7144
 DT Journal
 LA German
 AB Triazoloquinazolones I (X = CR₂, N; R = H, iodo; R₁ = 2-, 3-, 4-iodo, H; R₂ = H, Me, CH₂CO₂Et, OH, SH, Pr, Bu, Ph, CO₂Et) were obtained in 33-100% yield by cyclizing the hydrazines II (R₂ = H) with carboxylic acids or urea. II (R₂ = H) were obtained by hydrazinolysis of the thiols. Treatment of II (R₂ = H) with R₃NCX₁ (R₃ = Ph, 1-naphthyl; X₁ = O, S) gave II (R₂ = CX₁NHR₃).
 IT **77066-20-7P 77747-36-5P 77747-37-6P**
77747-38-7P 77747-39-8P 77775-32-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 77066-20-7 CAPLUS
 CN Hydrazinecarbothioamide, 2-(3,4-dihydro-6-iodo-4-oxo-3-phenyl-2-quinazolinyl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 77747-36-5 CAPLUS
 CN Hydrazinecarbothioamide, 2-[3,4-dihydro-3-(2-iodophenyl)-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 77747-37-6 CAPLUS
 CN Hydrazinecarboxamide, 2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)



nov.


RN 77747-38-7 CAPLUS

CN Hydrazinecarboxamide, 2-[3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)



RN 77747-39-8 CAPLUS


CN Hydrazinecarboxamide, 2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-1-naphthalenyl- (9CI) (CA INDEX NAME)



RN 77775-32-7 CAPLUS


CN Hydrazinecarboxamide, 2-[3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)

08/812,508




Q no ✓

L15 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1981:175041 CAPLUS
 DN 94:175041
 TI Synthesis of some novel quinazolone thiosemicarbazide and thiazoline derivatives for potential antimicrobial activity
 AU Omar, A. Mohsen M. E.; El-Dine, S. A. Shams; Ghobashy, A. A.; Khalil, M. A.
 CS Fac. Pharm., Univ. Alexandria, Alexandria, Egypt
 SO European Journal of Medicinal Chemistry (1981), 16(1), 77-80
 CODEN: EJMCA5; ISSN: 0009-4374
 DT Journal
 LA English
 AB Thiosemicarbazides I (R1 = allyl, optionally substituted Ph, PhCH2, R2 = optionally substituted Ph, PhCH2, allyl, Bu), possessing significant gram-pos. bactericidal activity, were prepd. in 60-92% yields from 4-oxoquinazoline-2-thiones by reaction with N2H4.H2O, followed by addn. of R2NCS. Cyclocondensation of I with R3COCH2Br (R3 = Ph, 4-ClC6H4) gave 63-85% II (R1,R2 as above).
 IT 67443-04-3P 67443-05-4P 67443-06-5P
 67443-09-8P 77437-06-0P 77437-08-2P
 77437-09-3P 77437-10-6P 77437-11-7P
 77437-13-9P 77437-14-0P 77437-16-2P
 77437-17-3P 77437-18-4P 77437-19-5P
 77437-20-8P 77437-22-0P 77437-24-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and cyclocondensation with bromoacetophenones)
 RN 67443-04-3 CAPLUS
 CN Hydrazinecarbothioamide, 2-[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 67443-05-4 CAPLUS
 CN Hydrazinecarbothioamide, 2-[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 67443-06-5 CAPLUS
 CN Hydrazinecarbothioamide, 2-[3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)

quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 67443-09-8 CAPLUS

CN Hydrazinecarbothioamide, 2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 77437-06-0 CAPLUS

CN Hydrazinecarbothioamide, 2-[3,4-dihydro-4-oxo-3-(2-propenyl)-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 77437-08-2 CAPLUS

CN Hydrazinecarbothioamide, 2-(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 77437-09-3 CAPLUS

CN Hydrazinecarbothioamide, 2-[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 77437-10-6 CAPLUS

CN Hydrazinecarbothioamide, N-butyl-2-[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 77437-11-7 CAPLUS

CN Hydrazinecarbothioamide, 2-[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 77437-13-9 CAPLUS

CN Hydrazinecarbothioamide, 2-[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 77437-14-0 CAPLUS

CN Hydrazinecarbothioamide, N-butyl-2-[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 77437-16-2 CAPLUS

CN Hydrazinecarbothioamide, 2-[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 77437-17-3 CAPLUS

CN Hydrazinecarbothioamide, N-(4-bromophenyl)-2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 77437-18-4 CAPLUS

CN Hydrazinecarbothioamide, 2-[3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-butyl- (9CI) (CA INDEX NAME)




RN 77437-19-5 CAPLUS

CN Hydrazinecarbothioamide, N-(4-bromophenyl)-2-[3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 77437-20-8 CAPLUS

CN Hydrazinecarbothioamide, 2-[3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 77437-22-0 CAPLUS


CN Hydrazinecarbothioamide, 2-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 77437-24-2 CAPLUS

CN Hydrazinecarbothioamide, 2-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-

quinazolinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




IT 77437-07-1P 77437-12-8P 77437-15-1P

77437-21-9P 77437-23-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn., cyclocondensation with bromoacetophenones, and bactericidal activity of)



RN 77437-07-1 CAPLUS

CN Hydrazinecarbothioamide, N-(4-bromophenyl)-2-[3,4-dihydro-4-oxo-3-(2-propenyl)-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 77437-12-8 CAPLUS

CN Hydrazinecarbothioamide, N-(4-bromophenyl)-2-[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 77437-15-1 CAPLUS

CN Hydrazinecarbothioamide, N-(4-bromophenyl)-2-[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 77437-21-9 CAPLUS

CN Hydrazinecarbothioamide, 2-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 77437-23-1 CAPLUS


CN Hydrazinecarbothioamide, N-(4-bromophenyl)-2-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]- (9CI) (CA INDEX NAME)




L15 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1981:132238 CAPLUS
 DN 94:132238
 TI Antianaphylactic effects of 2-hydrazino-3-arylquinazol-4-ones and
 4-aryl-5-oxo-4,5-dihydro-sym-triazolo[4,3-a]quinazolines
 AU Renner, H.; Schnitzler, S.; Hagen, V.; Kottke, K.; Kuehmstedt, H.
 CS Inst. Wirkstofforsch., Akad. Wiss., Berlin, DDR-1136, Ger. Dem. Rep.
 SO Pharmazie (1980), 35(12), 801-2
 CODEN: PHARAT; ISSN: 0031-7144
 DT Journal
 LA German
 AB Several 2-hydrazino-3-arylquinazol-4-ones (I; R1 = H or I; R2 = p-I,
 o,p-Me2, H, m,p-Me2, o,m-Me2; R3 = NH2, N:CMe2, NHC:SNHPh, etc.) and
 4-aryl-5-oxo-4,5-dihydro-s-triazolo[4,3-a]quinazolines (II; R1 = H or I;
 R2 = m-, p-, or o-substituted halogens, or Me, or Et; R3 = H, OH, Ph etc.)
 were effective inhibitors of active- or passive cutaneous anaphylaxis in
 rats. No structure activity relation was evident.
 IT **77066-19-4 77066-20-7 77066-21-8**
77066-22-9 77066-23-0
 RL: BIOL (Biological study)
 (anaphylaxis inhibition by, structure in relation to)
 RN 77066-19-4 CAPLUS
 CN Hydrazinecarbothioamide, 2-[3,4-dihydro-3-(4-iodophenyl)-4-oxo-2-
 quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 77066-20-7 CAPLUS
 CN Hydrazinecarbothioamide, 2-(3,4-dihydro-6-iodo-4-oxo-3-phenyl-2-
 quinazolinyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 77066-21-8 CAPLUS
 CN Hydrazinecarbothioamide, 2-[3-(2,3-dimethylphenyl)-3,4-dihydro-4-oxo-2-
 quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 77066-22-9 CAPLUS

CN Hydrazinecarbothioamide, 2-[3-(3,4-dimethylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 77066-23-0 CAPLUS


CN Hydrazinecarbothioamide, 2-[3-(2,4-dimethylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




L15 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1978:529469 CAPLUS
 DN 89:129469
 TI Synthesis of compounds with an aminoguanidine structure. Part 2.
 4-Aryl-5-oxo-1-thioxo-1,2,4,5-tetrahydro-s-triazolo[4.3-a]quinazoline and
 derivatives
 AU Kottke, K.; Kuehmstedt, H.
 CS Sekt. Pharm., Ernst-Moritz-Arndt-Univ., Greifswald, Ger. Dem. Rep.
 SO Pharmazie (1978), 33(2-3), 124-5
 CODEN: PHARAT; ISSN: 0031-7144
 DT Journal
 LA German
 AB Fourteen triazoloquinazolines I (R = H, Me, MeO, F, Cl, Br) were prepd. by
 cyclization of the quinazolines II (R1 = H) with CS2. II (R = H, Me, MeO,
 Cl, Br, R1 = H) were treated with PhNHCS to give II (R1 = PhNHCS).
 IT 67443-03-2P 67443-04-3P 67443-05-4P
 67443-06-5P 67443-07-6P 67443-08-7P
 67443-09-8P 67443-10-1P 67443-11-2P
 67443-12-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 67443-03-2 CAPLUS
 CN Hydrazinecarbothioamide, 2-(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)-N-
 phenyl- (9CI) (CA INDEX NAME)



RN 67443-04-3 CAPLUS
 CN Hydrazinecarbothioamide, 2-[3,4-dihydro-3-(2-methylphenyl)-4-oxo-2-
 quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 67443-05-4 CAPLUS
 CN Hydrazinecarbothioamide, 2-[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-
 quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 67443-06-5 CAPLUS

CN Hydrazinecarbothioamide, 2-[3-(4-bromophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 67443-07-6 CAPLUS

CN Hydrazinecarbothioamide, 2-[3-(2-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 67443-08-7 CAPLUS

CN Hydrazinecarbothioamide, 2-[3-(3-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 67443-09-8 CAPLUS

CN Hydrazinecarbothioamide, 2-[3-(4-chlorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 67443-10-1 CAPLUS

Hydrazinecarbothioamide, 2-[3,4-dihydro-3-(2-methoxyphenyl)-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 67443-11-2 CAPLUS

CN Hydrazinecarbothioamide, 2-[3,4-dihydro-3-(3-methoxyphenyl)-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 67443-12-3 CAPLUS

CN Hydrazinecarbothioamide, 2-[3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-2-quinazolinyl]-N-phenyl- (9CI) (CA INDEX NAME)



L15 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1974:520567 CAPLUS
 DN 81:120567
 TI Pyrimidines and condensed derivatives. III. Synthesis of some
 isocytosines and related imidazo[1,2-a]- and [1,2-c]pyrimidinones
 AU Agai, Bela; Hornyak, Gyula; Lempert, Karoly
 CS Dep. Org. Chem., Tech. Univ. Budapest, Budapest, Hung.
 SO Periodica Polytechnica, Chemical Engineering (1974), 18(1), 47-72
 CODEN: PDPTAE; ISSN: 0324-5853
 DT Journal
 LA English
 AB Isocytosines I-III [R = CH₂CH₂OH, (CH₂)₃OH, CH₂CO₂H, Bu, CH₂Ph, R₁ = H;
 RR₁ = (CH₂)₃-4; R₂ = H, Me, Et; R₃ = H, allyl; R₄ = Me, 2-butenyl,
 CH₂CH₂CO₂H; R₃R₄ = (CH₂)₃-4] were prepd. by aminolysis of the
 corresponding methylthio compds., obtained by methylating appropriate
 thiouracils. I-III (R = CH₂CH₂OH) were chlorinated and cyclized to
 imid-azopyrimidinones.
 IT **54069-46-4P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 54069-46-4 CAPLUS
 CN 2,4(1H,3H)-Quinazolin-6-one, 5,6,7,8-tetrahydro-, 2-[(2-
 hydroxyethyl)hydrazone] (9CI) (CA INDEX NAME)



L15 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1961:54307 CAPLUS

DN 55:54307

OREF 55:10450e-i,10451a-i,10452a-h

TI Pyrimidine derivatives. IX. Mercapto-s-triazolopyrimidines

AU Shirakawa, Kenzo

CS Takeda Pharm. Inds. Ltd., Osaka

SO Yakugaku Zasshi (1960), 80, 1542-50

CODEN: YKKZAJ; ISSN: 0031-6903

DT Journal

LA Unavailable

AB cf. CA 54, 24761h. NaOH (1.3 g.) in 40 ml. 50% EtOH treated with 4.2 g. 2-hydrazino-4-hydroxy-6-methylpyrimidine (I) and 3 ml. CS₂, the mixt. refluxed 4 hrs., and the product filtered off gave Na salt of 3-mercapto-5-hydroxy-7-methyl-s-triazolo[4,3-a]pyrimidine (II); the filtrate acidified with AcOH gave 1.9 g. 3-mercapto-5-methyl-7-hydroxy-s-triazolo[4,3-a]pyrimidine (III), m. 287.degree. (decompn.); the Na salt of II and AcOH gave the free II, m. 285.degree. (decompn.). There was no depression of m.p. by mixing the free II and III but the R_f of free II was 0.50 and that of III was 0.62. Isomerization of the free II. Solid paraffin (5 g.) at 250-5.degree. treated with 0.7 g. free II, the mixt. kept 5 min., cooled, the paraffin extd. with C₆H₆, the insol. residue taken up in dil. NH₄OH, acidified with AcOH, and the product filtered off gave III, m. 287.degree. (decompn.). I (14 g.) in 500 ml. hot 50% EtOH treated with 13.5 g. PhNCS, the mixt. kept overnight, the product filtered off, and washed with hot EtOH gave 24.5 g. 1-(4-hydroxy-6-methyl-2-pyrimidyl)-4-phenyl-3-thiosemicarbazide (IV), m. 277.degree. (decompn.). IV (10 g.) and 15 g. molten paraffin at 210-20.degree. kept 5 min., cooled, the paraffin washed with C₆H₆, and the insol. residue in hot H₂O recrystd. (HCONH₂) gave 5.6 g. III, m. 287.degree. (decompn.). The free II (1.5 g.) in 50 ml. 1% NH₄OH and 6 g. Raney Ni refluxed 1.5 hrs., the soln. filtered hot, the filtrate refluxed 1 hr. with 4 g. Ni catalyst, the soln. concd., and acidified with AcOH gave 0.7 g. 5-hydroxy-7-methyl-s-triazolo[4,3-a]-pyrimidine (V), m. 251.degree. and 278.degree.. III (1 g.) in 25 ml. 10% H₂SO₄ at 50-5.degree. treated with 2.5 g. NaNO₂, the mixt. kept 10 min., and NaHCO₃ added until the soln. remained weakly alk. gave 0.7 g. 5-methyl-7-hydroxy-s-triazolo[4,3-a]pyrimidine (VI), m. 300.degree. (decompn.) (H₂O). III (1 g.) in 20 ml. H₂O while refluxing treated dropwise with 2.1 g. 30% H₂O₂, the soln. concd., and neutralized with NaHCO₃ gave 0.61 g. VI. III with Raney Ni in 1% NH₄OH gave VI. III (2.6 g.) in 40 ml. 4% NH₄OH at 10-13.degree. treated with 4.8 g. KMnO₄ portionwise, the soln. decolorized by adding EtOH, filtered, the filtrate acidified with H₂SO₄, and concd. gave 3 g. VI 3-sulfonic acid deriv., m. 300.degree. (decompn.). 2-Hydrazino-4-hydroxy-6-phenylpyrimidine (VII) (6 g.) in 60 ml. 1:1 C₅H₅N-H₂O and 9 ml. CS₂ refluxed 10 hrs., cooled, and the product recrystd. (AcOH) gave 3.4 g. 3-mercapto-5-phenyl-7-hydroxy-s-triazolo[4,3-a]pyrimidine-AcOH (VIII), m. 258-9.degree. (decompn.); the mother liquor from VIII concd. and the residue recrystd. (dil. AcOH) gave 3-mercapto-5-hydroxy-7-phenyl-s-triazolo[4,3-a]pyrimidine (IX), m. 257-8.degree. (decompn.). The sepn. of VIII and IX was difficult but VIII showed R_f 0.60; that of IX was 0.70. IX (1 g.) in 10 ml. 8% NaOH at 0.degree. treated dropwise with 1.5 ml. 30% H₂O₂, the mixt. kept a while at room temp., heated 15 min. at 40.degree., cooled and the soln. acidified gave 0.45 g. 5-hydroxy-7-phenyl-s-triazolo[4,3-a]pyrimidine (X), m. 237-8.degree. and 293-4.degree.. IX in dil. NH₄OH with Raney Ni did not give X but gave .beta.- or .gamma.-form crystals of 2-amino-4-hydroxy-6-phenyl-pyrimidine, m. 303.degree. (decompn.). VII (18.5 g.) in 500 ml. hot 80% EtOH treated with 12.5 g. PhNCS and the


product filtered off gave 30 g. 1-(4-hydroxy-6-phenyl-2-pyrimidyl)-4-phenyl-3-thiosemicarbazide (XI), m. 198-202.degree.. XI (5 g.) heated 5 min. at 250.degree., cooled, and the product washed with C6H6 gave 3.5 g. 2-anilino-4-hydroxy-6-phenylpyrimidine (XII), needles, m. 281.degree. (95% AcOH). 2-Nitroamino-4-hydroxy-6-phenylpyrimidine (1 g.) and 1 ml. PhNH2 heated gently to 190.degree. and the product washed with C6H6 gave XII, m. 280-1.degree.. IX (0.3 g.) and 3 ml. PhNH2 refluxed 5 min. and the product washed with C6H6 gave 0.08 g. XII, m. 280-1.degree.. 2-Hydrazino-4-hydroxy-5,6-tetramethylenepyrimidine (XIII) (3.6 g.) in 100 ml. 70% EtOH at 60.degree. treated with 2.7 g. PhNCS in 10 ml. EtOH and heated at 60-70.degree. gave 3.8 g. 1-(4-hydroxy-5,6-tetramethylene-2-pyrimidyl)-4-phenyl-3-thiosemicarbazide (XIV), m. 287-8.degree. (decompn.). XIII (6 g.) in 40 ml. 1:1 C5H5N-H2O and 6 ml. CS2 refluxed 4 hrs. and the product filtered gave 2.5 g. 3-mercapto-5,6-tetramethylene-7-hydroxy-s-triazolo[4,3-a]pyrimidine (XV), plates, m. 310.degree. (decompn.) (70% HCO2H); the mother liquor from XV concd. gave 0.12 g. C9H10ON4S, columns, m. 296.degree. (decompn.). XIV (10.5 g.) in 15 g. paraffin heated 10 min. at 220.degree., the product washed with C6H6, and the residue recrystd. (HCONH2) gave 4.8 g. XV, m. 310.degree. (decompn.). XV (1.5 g.) in 40 ml. 1.5% NH4OH and 12 g. Raney Ni refluxed 1.5 hrs. and the product recrystd. (H2O) gave 0.21 g. 5,6-tetramethylene-7-hydroxy-s-triazolo[4,3-a]pyrimidine, needles, m. 268-70.degree. (decompn.). The reaction of 2-hydrazino-4-hydroxy-5,6-trimethylenepyrimidine and an equiv. amt. of PhNCS gave 1-(4-hydroxy-5,6-trimethylene-2-pyrimidyl)-4-phenyl-3-thiosemicarbazide (XVI), m. 285.degree. (decompn.). XVI (6 g.) and 10 g. paraffin heated 5 min. at 215-20.degree., the product washed with C6H6, the insol. residue taken up in 4% NH4OH, and acidified with AcOH gave 3.9 g. 3-mercapto-5,6-trimethylene-7-hydroxy-s-triazolo[4,3-a]pyrimidine (XVII), m. 285.degree. (decompn.). XVII (1.5 g.) and Raney Ni treated as XV above gave 0.5 g. 5,6-trimethylene-7-hydroxy-s-triazolo[4,3-a]pyrimidine, m. 301.degree. (decompn.). 2-Hydrazino-3-benzyl-6-methyl-4(3H)-pyrimidinone (0.5 g.) in 5 ml. C5H5N and 1 ml. CS2 refluxed 15 min., an equal amt. of H2O added, and the mixt. cooled gave 0.54 g. 3-mercapto-5-methyl-8 benzyl-s-triazolo[4,3-a]pyrimidin-7(8H)-one, m. 315.degree. (decompn.). 2-Hydrazino-4-hydroxy-6-methylpyrimidine (21 g.) in 80 ml. 15% NaOH at 5.degree. treated dropwise with 18 g. ClCO2Et, the mixt. kept 2 hrs., AcOH added to pH 5.5, and the product recrystd. (94% EtOH) gave 22.6 g. 2-ethoxycarbonylhydrazino deriv., m. 222.degree.; this (1 g.) fused at 240-50.degree. gave 0.7 g. 3,7-dihydroxy-5-methyl-s-triazolo[4,3-a]pyrimidine, m. 325.degree. (decompn.). XIII (9 g.) in 200 ml. H2O treated with concd. HCl to pH 4, the soln. at 25.degree. treated with 5.7 g. KCNO in 100 ml. H2O, stirred 20 min., kept overnight, and the product filtered off gave 1-(4-hydroxy-5,6-tetramethylene-2-pyrimidyl)-3-semicarbazide, needles, m. 232.degree. (decompn.) and 300-8.degree.; this (1.3 g.) heated 10 min. at 235-40.degree., the product taken up in hot AcOH, filtered with C, and dild. with H2O gave 0.9 g. 3,7-dihydroxy-5,6-tetramethylene-s-triazolo-[4,3-a]pyrimidine, m. 309.degree. (decompn.). 2-Hydrazino-4-methylpyrimidine (6.2 g.) in 50 ml. H2O and 45 ml. 10% NaOH at 0.degree. treated with 6.5 g. ClCO2Et portionwise and kept for a while gave 2-ethoxycarbonylhydrazino-4-methyl-pyrimidine, plates, m. 140-2.degree. (C6H6-ligroine); this did not cyclize on heating at 250.degree.. 2-Hydrazino-4,6-dimethylpyrimidine (6.9 g.) in 100 ml. 80% EtOH contg. 2 g. NaOH and 7 ml. CS2 refluxed 2 hrs., cooled, the ppt. of 3-NaS deriv. filtered off, the filtrate concd., and the residue acidified with AcOH gave 0.4 g. 2-HS deriv., needles, m. 255.degree. (decompn.) (EtOH); the 3-NaS deriv. in H2O acidified with AcOH gave 3.5 g. 3-mercapto-5,7-dimethyl-s-triazolo[4,3-a]pyrimidine (XVIII), needles, m. 255.degree. (decompn.). XVIII (0.05 g.) in 10 ml. H2O boiled 10 hrs. and

the products chromatographed on paper gave 0.04 g. 3-mercapto-5,7-dimethyl-s-triazolo[2,3-a]pyrimidine (XIX), m. 251.degree. (decompn.), and a substance assumed to be 3-mercapto-5-amino-s-triazole. XVIII (0.03 g.) in 6 ml. 1% NaOH kept at room temp. and the product chromatographed on paper indicated the formation of XIX. 2-Hydrazino-4,6-dimethylpyrimidine (13.8 g.) in 150 ml. hot 70% EtOH treated with 13.5 g. PhNCS and left standing gave 26.3 g. 1-(4,6-dimethyl-2-pyrimidyl)-4-phenyl-3-thiosemicarbazide (XX), needles, m. 186.5.degree. (decompn.). XX (5 g.) fused 6 min. at 195-200.degree. and the product extd. with Et2O gave 1.7 g. XIX, m. 255.degree. (decompn.) (MeOCH2CH2OH); the mother liquor gave 0.15 g. (PhNH)2CS, m. 151-3.degree.. XVIII (1 g.) in 1 ml. 30% NH4OH and 23 ml. H2O refluxed 30 min. with 4 g. Raney Ni and the product concd. gave 0.1 g. 5,7-dimethyl-s-triazolo[4,3-a]pyrimidine, needles, m. 165-7.degree. [HC(OEt)3dioxane]. XIX (0.1 g.) in 3 ml. AcOH and 0.2 ml. 30% H2O2 refluxed 10 min., the soln. concd., and the residue in H2O and K2CO3 extd. with C6H6 gave 0.01 g. 5,7-dimethyl-s-triazolo[2,3-a]pyrimidine, m. 135-6.degree.. 2-Hydrazinopyrimidine (2.2 g.) in 20 ml. 80% EtOH contg. 0.8 g. Na and 3 ml. CS2 refluxed 2 hrs., cooled to ppt. the Na salt of 3-mercapto-s-triazolo[4,3-a]pyrimidine (XXI), the filtrate concd., and the residue acidified with AcOH gave 0.1 g. 2-HS analog of XXI, plates, m. 245.degree. (decompn.); the Na salt of XXI treated with AcOH and the product recrystd. (99% EtOH) gave 0.78 g. XXI, needles, m. 242.degree. (decompn.). XXI isomerized to 2-mercapto-s-triazolo[2,3-a] pyrimidine (XXII) by boiling in 50% C5H5N-H2O or in H2O. 2-Hydrazinopyrimidine (5 g.) in 8 ml. CS2 and 40 ml. C5H5N refluxed 3.5 hrs., the soln. filtered, the filtrate concd., the residue washed with H2O, taken up in dil. alkali, and acidified with AcOH gave 3.2 g. 3-mercapto-5-amino-s-triazole (XXIII), m. 309.degree. (decompn.). XXIII (0.2 g.) in 10 ml. H2O treated with 0.6 g. 30% H2O2, refluxed 15 min., cooled, 0.25 g. NaHCO3 and 0.45 g. picric acid added gave 5-amino-s-triazole picrate, m. 229-31.degree.. XXI (0.32 g.) in 10 ml. 1% NH4OH and 3.5 g. Raney Ni refluxed 1.5 hrs., the soln. concd., and the residue extd. with C6H6 gave s-triazolo[2,3-a]pyrimidine, needles, m. 141-3.degree.. 1-(2-Pyrimidyl)-4-phenyl-3-thiosemicarbazide (4.9 g.), m. 184-5.degree. (prepd. from 2-hydrazinopyrimidine and PhNCS), fused 4 min. at 190.degree., the product treated with 1:1 EtOH-C6H6, and filtered gave 0.8 g. XXIII, m. 308.degree. (decompn.); the mother liquor gave 1.5 g. (PhNH)2CS, m. 151-3.degree.. 2-Hydrazino-4-methylpyrimidine (12.4 g.) in 80 ml. 50% EtOH contg. 4 g. NaOH and 10 ml. CS2 refluxed 4 hrs. and cooled gave ppt. of Na salt of 3-mercapto-5-methyl-s-triazolo[4,3-a]pyrimidine (XXIV); the filtrate acidified with AcOH gave 3.8 g. 7-Me analog (XXV) of XXIV, m. 255.degree. (decompn.). The Na salt of XXIV treated with dil. AcOH and the product recrystd. (70% EtOH) gave 3.1 g. XXIV, m. 255.degree. (decompn.). XXIV and XXV showed no depression of m.p. on mixing and had the same Rf. XXIV (0.3 g.) in 1 ml. H2O and 0.3 ml. C5H5N refluxed 20 min., the soln. concd., and the residue in 3 ml. H2O acidified gave 0.27 g. 2-mercapto-7-methyl-1,2,4-triazolo[2,3-a]pyrimidine (XXVI), prisms, m. 247.degree. (decompn.). Similarly, XXV yielded 5-Me analog (XXVII) of XXVI, m. 249.degree. (decompn.). XXIV (0.4 g.) in 10 ml. 1% NH4OH and 3 g. Raney Ni refluxed 1.5 hrs., the soln. concd., the residue in 5 ml. 10% NH4OH refluxed 1.5 hrs., and the product recrystd. (C6H6-ligroine) gave 0.19 g. 7-methyl-s-triazolo[2,3-a]pyrimidine (XXVII), m. 136-8.degree.. Similarly, 6 g. XXV yielded 1.2 g. 5-Me analog of XXVII, prisms, m. 180-2.degree..

IT 98961-67-2, Semicarbazide, 1-(5,6,7,8-tetrahydro-4-hydroxy-2-quinazolinyl)- 109340-09-2, Semicarbazide, 4-phenyl-1-(5,6,7,8-tetrahydro-4-hydroxy-2-quinazolinyl)-3-thio-
(prepn. of)


RN 98961-67-2 CAPLUS

CN Semicarbazide, 1-(5,6,7,8-tetrahydro-4-hydroxy-2-quinazolinyl)- (6CI) (CA INDEX NAME)



RN 109340-09-2 CAPLUS

CN Semicarbazide, 4-phenyl-1-(5,6,7,8-tetrahydro-4-hydroxy-2-quinazolinyl)-3-thio- (6CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 19:50:32 ON 11 SEP 2003)

FILE 'REGISTRY' ENTERED AT 19:50:37 ON 11 SEP 2003

```

L1      SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L2      STRUCTURE UPLOADED
L3      QUE L2 NOT L1
L4      14 S L3 SSS SAM
L5      SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L6      STRUCTURE UPLOADED
L7      QUE L6 NOT L5
L8      0 S L7 SSS SAM
L9      0 S L7 SSS FUL
L10     SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047
L11     STRUCTURE UPLOADED
L12     QUE L11 NOT L10
L13     14 S L12 SSS SAM
L14     198 S L12 SSS FUL

```

FILE 'CAPLUS' ENTERED AT 19:54:34 ON 11 SEP 2003

```

L15     27 S L14

```

FILE 'CAOLD' ENTERED AT 19:55:17 ON 11 SEP 2003

=> s 114


```

L16     1 L14


```

=> d bib,hitstr

L16 ANSWER 1 OF 1 CAOLD COPYRIGHT 2003 ACS on STN
 AN CA55:10450e CAOLD
 TI pyrimidine derivs. - (IX) mercapto-s-triazolopyrimidines, (X)
 N-benzyl-s-triazolopyrimidinones
 AU Shirakawa, Kenzo
 IT 98961-67-2 109340-09-2
 RN 98961-67-2 CAOLD
 CN Semicarbazide, 1-(5,6,7,8-tetrahydro-4-hydroxy-2-quinazolinyl)- (6CI) (CA INDEX NAME)



RN 109340-09-2 CAOLD
 CN Semicarbazide, 4-phenyl-1-(5,6,7,8-tetrahydro-4-hydroxy-2-quinazolinyl)-3-thio- (6CI) (CA INDEX NAME)



08/812,508

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

3.02

424.42

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION


CA SUBSCRIBER PRICE

0.00

-17.58

STN INTERNATIONAL LOGOFF AT 19:55:37 ON 11 SEP 2003

L15 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1983:505201 CAPLUS
 DN 99:105201
 TI Synthesis of the 1,2,4-triazolo[4,3-a]quinazolin-5-ones and related compounds
 AU El-Sherief, H. A.; Abdel-Rahman, A. E.; El-Naggar, G. M.; Mahmoud, A. M.
 CS Fac. Sci., Assiut Univ., Assiut, Egypt
 SO Bulletin of the Chemical Society of Japan (1983), 56(4), 1227-30
 CODEN: BCSJA8; ISSN: 0009-2673
 DT Journal
 LA English
 OS CASREACT 99:105201
 AB Heating hydrazinoquinazolinone I with RCO₂H (R = H, Me, Et), R₁C₆H₄CHO (R₁ = H, 3-Cl, 4-Cl, 4-Me, 4-MeO), or CS₂ gave triazoloquinazolines II (R₂ = R, R₁C₆H₄, SH) resp. Refluxing I with MeCOCH₂CO₂Et in EtOH gave the corresponding hydrazone which was heated to give pyrazoline III.
 IT **86842-47-9P 86842-56-0P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and cyclization of, triazoloquinazoline from)
 RN 86842-47-9 CAPLUS
 CN Acetic acid, 2-(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)hydrazide (9CI)
 (CA INDEX NAME)



RN 86842-56-0 CAPLUS
 CN Benzoic acid, 2-(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)hydrazide (9CI)
 (CA INDEX NAME)

